COMMANDS研究:突变谱与突变负荷对低危MDS红细胞输注反应的影响
COMMANDS试验已确立罗特西普为输血依赖型低危MDS贫血的一线治疗。本分析基于350例可评估患者的体细胞突变谱与疾病风险,比较罗特西普与阿法依泊汀的红细胞输注反应。罗特西普在多种突变背景、VAF≥10%、1-3个突变及全部IPSS-M风险组中反应均优于阿法依泊汀,在伴环形铁粒幼细胞者中优势明显。
要点
- 罗特西普在SF3B1突变型LR-MDS中反应优于阿法依泊汀,风险差0.38(95%CI 0.25-0.50)。
- VAF≥10%患者中罗特西普反应优势明显,随机效应RD 0.36(95%CI 0.28-0.44)。
- 伴环形铁粒幼细胞者多数突变下罗特西普反应更优,RS阴性者两药反应相近。
核心结论
- 在COMMANDS试验中,罗特西普在多种体细胞突变背景下对LR-MDS贫血的红细胞输注反应优于阿法依泊汀。
- 罗特西普的获益在VAF≥10%、携带1-3个突变及所有IPSS-M风险组中均可见。
- 伴环形铁粒幼细胞患者的罗特西普反应优势明显,而RS阴性患者两治疗组反应相似。
研究设计与样本
- COMMANDS试验(NCT03682536)中罗特西普对比阿法依泊汀治疗输血依赖型LR-MDS的RBC输注反应分析。
- 共350例可评估患者,238例(68.0%)按WHO 2016标准为伴多系病态造血和环形铁粒幼细胞的MDS。
- 320例(91.4%)携带≥1个体细胞突变(中位数2个),中位VAF为2%-59%,两治疗组突变谱相似。
主要发现
- 罗特西普在多种突变中反应优于阿法依泊汀,风险差RD 0.25(95%CI 0.15-0.35)。
- SF3B1突变型RD 0.38(95%CI 0.25-0.50),SF3B1野生型RD 0.09(95%CI -0.11至0.30)。
- VAF≥10%者随机效应0.36(95%CI 0.28-0.44);1、2、3个突变者反应率分别为63% vs 40%(p=0.040)、70% vs 27%(p<0.001)、72% vs 40%(p=0.018)。
- IPSS-M低、中低、中高、高危组反应率分别为75% vs 38%、61% vs 38%、44% vs 21%、36% vs 24%,汇总效应RD 0.26(95%CI 0.14-0.37)。
- 伴RS者多数突变下罗特西普反应更优(随机效应0.34,95%CI 0.24-0.44),RS阴性者两药相似。
关键数值与推荐
- SF3B1突变型风险差0.38(95%CI 0.25-0.50),SF3B1野生型0.09(95%CI -0.11至0.30)。
- VAF≥10%者随机效应0.36(95%CI 0.28-0.44)。
- 1、2、3个突变者反应率比较分别为63% vs 40%(p=0.040)、70% vs 27%(p<0.001)、72% vs 40%(p=0.018)。
- IPSS-M四组汇总效应RD 0.26(95%CI 0.14-0.37);伴RS者随机效应0.34(95%CI 0.24-0.44)。
临床怎么用
- 对输血依赖型LR-MDS,罗特西普可作为多种突变背景(含SF3B1野生型)及不同IPSS-M风险组的一线贫血治疗选择。
- VAF≥10%或携带多个突变者使用罗特西普的反应优势更明显,可结合突变负荷辅助治疗决策。
- 伴环形铁粒幼细胞者优先考虑罗特西普;RS阴性者罗特西普与阿法依泊汀反应相近,需个体化选择。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COMMANDS trial established luspatercept as a first-line treatment for anemia in transfusion-dependent lower-risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS trial. Of 350 evaluable patients, 238 (68.0%) had MDS with multiple lineage dysplasia and ring sideroblasts (RS) according to World Health Organization 2016 criteria, and 320 (91.4%) had somatic mutations in ≥ 1 gene (median, 2) with median variant allele frequencies (VAF) of 2%-59%. Mutation profiles were similar in the treatment groups. Luspatercept had superior responses versus epoetin alfa across multiple mutations (risk difference; RD, [95% confidence interval; CI] 0.25 [0.15-0.35]), including in SF3B1-mutated (0.38 [0.25-0.50]) and SF3B1 wild-type (0.09 [-0.11 to 0.30]). Luspatercept demonstrated superior responses in patients with VAF ≥ 10% (random effect, 0.36 [95% CI, 0.28-0.44]), and in those with 1 (63% vs. 40%; p = 0.040), 2 (70% vs. 27%; p < 0.001), and 3 (72% vs. 40%; p = 0.018) mutations, and across the low (75% vs. 38%), moderate low (61% vs. 38%), moderate high (44% vs. 21%), and high (36% vs. 24%) Molecular International Prognostic Scoring System risk groups (summary effect RD, 0.26 [95% CI, 0.14-0.37]). Across most mutations luspatercept responses were superior (random effect, 0.34 [95% CI, 0.24-0.44]) in patients with RS but were similar between treatments in RS-negative patients. Luspatercept represents an effective treatment option in various mutational backgrounds in LR MDS. Trial Registration: ClinicalTrials.gov Identifier: NCT03682536.
引用
- Komrokji RS, Hayati S, Ugidos M, et al. Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. Am J Hematol. 2026. PMID: 41549790. doi:10.1002/ajh.70171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。